Salestools LogoSalestools
Agenti IA Salestools
Soluzioni
Risorse
Azienda
Prezzi
Salestools Logo

Salestools

L'agente IA #1 per team di vendita e Go-to-Market. Vendi di più, più velocemente, con meno sforzo.

Prodotto

  • Agenti di vendita IA
  • Dati di intenzione
  • Dati Tecnologici
  • Tracciamento Visitatori
  • Co-Pilota
  • Vendita Sociale

Soluzioni

  • Servizio Clienti
  • E-commerce
  • SaaS
  • Impresa
  • Piccole Imprese

Risorse

  • Il rapporto
  • Documentazione
  • Riferimento API
  • Centro assistenza
  • Blog
  • Casi studio
  • Webinar

Azienda

  • Chi siamo
  • Carriere
  • Stampa
  • Contatto
  • Partner

Le nostre sedi

  • New York, HQ
  • Bucarest, Laboratorio di Ricerca IA
  • Zug, Svizzera

© 2025 Salestools. Tutti i diritti riservati.

Termini sui Dati e SicurezzaPolitica sulla privacyTermini di servizio
Tutti i sistemi operativi
Salestools LogoSalestools
Agenti IA Salestools
Soluzioni
Risorse
Azienda
Prezzi
Back to The Report
Biotech

VectorIntelligence

VectorIntelligence Raises $400M Series D to Transform Biotech

$400M Series D
Total Raised
Series
Latest Round
2020
Founded
250-500
Employees
Seattle, WA
Updated October 4, 2025
1 min read

Quick Facts

Valuation
$5B
Latest Round Size
$400M Series D
Latest Round Date
October 2025

VectorIntelligence Raises $400M Series D in Latest Funding Round

VectorIntelligence has successfully closed a $400M Series D funding round, marking a significant milestone in the company's growth trajectory. The round was led by Andreessen Horowitz, with participation from NEA.

Company Overview

Founded in 2020 and headquartered in Seattle, WA, VectorIntelligence has established itself in the Biotech space. Leading machine learning platform automating enterprise workflows with advanced AI models

With a current valuation of $5B, the company has demonstrated strong market traction and investor confidence.

Investment Details

  • Amount Raised: $400M Series D
  • Valuation: $5B
  • Lead Investor: Andreessen Horowitz

Future Outlook

As VectorIntelligence moves forward with its expanded funding, the company is well-positioned to capitalize on market opportunities and drive innovation in the biotech space.

Key Investors

Andreessen Horowitz
Venture Capital
Leading venture capital firm investing in technology companies
NEA
Venture Capital
Leading venture capital firm investing in technology companies

Topics

Venture Capital(911)Technology(815)Startup Funding(564)Series(545)Biotech

About the Author

Emma Rodriguez
Emma Rodriguez
Senior venture capital analyst with 8+ years covering Series A to growth-stage investments across fintech and AI sectors.

Related Company Reports

Biotech
Orna Therapeutics

Orna Therapeutics Raises $251M Series B

Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases

Emma Rodriguez
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics

Forge Biologics Raises $120M Series C

Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology

Vir Biotechnology Raises $250M

Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$250M